Zacks Investment Research·20h ago
Is the Options Market Predicting a Spike in Prestige Consumer Healthcare Stock?Investors need to pay close attention to PBH stock based on the movements in the options market lately.
Prestige Consumer Healthcare Inc.(PBH)Earnings, Financials & Key Ratios
PBH•NYSE
$48.86
12.5× P/E·Price updated Jul 6, 2026
AboutPrestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.Show more
- Revenue$1.09B-4.3%
- EBITDA$341M-7.2%
- Net Income$190M-11.3%
- EPS (Diluted)3.91-8.9%
- Gross Margin52.78%-5.3%
- EBITDA Margin31.29%-3.0%
- Operating Margin28.42%-4.0%
- Net Margin17.48%-7.3%
- ROE10.22%-16.9%
PBH Price & Volume
Prestige Consumer Healthcare Inc. (PBH) stock price & volume — 10-year historical chart
Loading chart...
Persistent Organic Contraction Challenges Brand Equity Value
Investment Thesis • Updated 2026Q4
VerdictNeutral
Growth:Contracting
Profitability:Moderate
Financial:Healthy
Cash Flow:Stable
Primary Risk:Persistent organic revenue decline
Key Thesis Takeaways
- Prestige Consumer Healthcare faces a challenging outlook characterized by persistent organic revenue declines, which reached -5.1% in 2026Q4, signaling potential saturation in its legacy brand portfolio.
- While the company maintains a disciplined capital structure with a debt-to-equity ratio of 0.55, the reliance on inorganic growth to offset top-line weakness may face diminishing returns.
- Investors should monitor whether the recent gross margin compression to 50.0% reflects structural competitive pressures or temporary promotional intensity in a difficult retail environment.
Verdict Logic
while the company maintains a robust liquidity profile with a current ratio of 3.57, the persistent organic revenue decline of -5.1% in 2026Q4 warrants caution regarding the long-term sustainability of its current valuation.
PBH Growth Metrics
Prestige Consumer Healthcare Inc. (PBH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years3.05%
5 Years2.91%
3 Years-1.17%
TTM-4.31%
Profit CAGR
10 Years6.66%
5 Years2.93%
3 Years-
TTM-11.33%
EPS CAGR
10 Years7.6%
5 Years3.77%
3 Years-
TTM-8.86%
Return on Capital
10 Years7.09%
5 Years7.85%
3 Years10.09%
Last Year9.21%
PBH Recent Earnings
Prestige Consumer Healthcare Inc. (PBH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$1.23-11.5%
$1.39
Rev
$282M-4.1%
$294M
Q1 2026
Feb 5, 2026Metric
Actual
Est
EPS
$1.14-1.7%
$1.16
Rev
$283M+0.4%
$282M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.07+10.3%
$0.97
Rev
$274M-6.8%
$294M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.95-5.9%
$1.01
Rev
$250M-9.3%
$275M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $1.23vs $1.39-11.5% | $282Mvs $294M-4.1% |
| Q1 2026 | Feb 5, 2026 | $1.14vs $1.16-1.7% | $283Mvs $282M+0.4% |
| Q4 2025 | Nov 6, 2025 | $1.07vs $0.97+10.3% | $274Mvs $294M-6.8% |
| Q3 2025 | Aug 7, 2025 | $0.95vs $1.01-5.9% | $250Mvs $275M-9.3% |
Based on last 12 quarters of dataView full earnings history →
Latest PBH News
Recent stock market news and headlines for Prestige Consumer Healthcare Inc. (PBH)
GlobeNewsWire·1 day ago
Prestige Consumer Healthcare Inc. Completes Acquisition of LaCorium Health, Prices $400 Million Senior Notes Offering, and Announces First Quarter Fiscal 2027 Earnings Results DateTARRYTOWN, N.Y., July 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of LaCorium Health (“LaCorium”), priced a private offering of $400 million in senior notes, and will report its first quarter fiscal 2027 results on August 6, 2026.
Fool - Investing News·4 days ago
Alphabet Joined the Dow and Became a Top Holding in Berkshire Hathaway's Portfolio. But This Stock Could Be an Even Better Buy.This under-the-radar healthcare stock just made its biggest acquisition ever -- and it could easily outperform many of Wall Street's favorite names.
GlobeNewsWire·Jun 30, 2026
Prestige Consumer Healthcare Inc. Announces Offering of $400 Million Senior NotesTARRYTOWN, N.Y., June 30, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige Brands”), intends to offer, subject to market and other conditions, up to $400 million in aggregate principal amount of new senior notes due 2034 (the “notes”) in a private offering. The notes will be senior unsecured obligations of Prestige Brands and will be guaranteed by the Company and certain of its domestic subsidiaries.
PRNewsWire·Jun 25, 2026
Prestige Consumer Healthcare Inc. (PBH) Clear Eyes® and Pillar5 Problems Drive Stock Lower, HBSS InvestigatingSAN FRANCISCO, June 25, 2026 /PRNewswire/ -- Investors in Prestige Consumer Healthcare (NYSE: PBH) saw the price of their shares fall over 11% on May 14, 2026 after the company revealed significant revenue declines and production problems driving the company's disappointing Q4 2026 financial results. The surprise developments have prompted national shareholder rights firm Hagens Berman to open an investigation into whether, before May 14, Prestige was sufficiently transparent regarding its ability to remediate supply chain constraints and, if not, whether the company violated the federal securities laws.
Peers Comparison
Key metrics vs top competitors for Prestige Consumer Healthcare Inc. (PBH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $48.86 | $2.31B | 12.50 | -4.31% | 17.48% | 10.22% | — | |
| $83.44 | $1.94B | 21.62 | -5.23% | 4.48% | 6.65% | — | |
| $97.45 | $23.08B | 32.27 | 1.57% | 11.81% | 17.45% | — | |
| $21.34 | $1.46B | 6.43 | 2.28% | 6.55% | 116.9% | — | |
| $11.09 | $1.53B | -1.08 | -2.75% | -43.5% | -50.65% | — | |
| $2.25 | $1.98B | -5.11 | -3.68% | -9.26% | -14.13% | — |
Compare PBH vs Peers
Prestige Consumer Healthcare Inc. (PBH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PBH SEC Filings & Documents
Prestige Consumer Healthcare Inc. (PBH) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Feb 5, 2026·SEC
10-K Annual Reports
510-Q Quarterly Reports
6Get notified when PBH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PBH Frequently Asked Questions
Prestige Consumer Healthcare Inc. (PBH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Prestige Consumer Healthcare Inc.'s revenue?
Prestige Consumer Healthcare Inc. (PBH) reported $1.09B in revenue for fiscal year 2026. This represents a 12479% increase from $8.7M in 2001.
How fast is Prestige Consumer Healthcare Inc. growing?
Prestige Consumer Healthcare Inc. (PBH) saw revenue decline by 4.3% over the past year.
Is PBH profitable?
Yes, Prestige Consumer Healthcare Inc. (PBH) is profitable, generating $190.3M in net income for fiscal year 2026 (17.5% net margin).
Dividend & Returns
What is PBH's return on equity?
Prestige Consumer Healthcare Inc. (PBH) has a return on equity (ROE) of 10.2%. This is reasonable for most industries.
What is Prestige Consumer Healthcare Inc.'s free cash flow?
Prestige Consumer Healthcare Inc. (PBH) generated $254.2M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.